2.1
Pembrolizumab (Keytruda, Merck Sharp & Dohme) plus chemotherapy with or without bevacizumab is indicated for 'the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1'.
2 Information about pembrolizumab
Dosage in the marketing authorisation
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
Price
2.2
The list price is £2,630.00 per 100 mg/4 ml concentrate for solution for infusion vial (excluding VAT; BNF online accessed October 2023).
2.3
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.